Connect Biopharma Holdings Business Summary

Connect Biopharma Holdings Ltd (CNTB) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing and collaboration agreements, most notably an exclusive license with Simcere Pharmaceutical for the development and commercialization of its lead asset, rademikibart, in Greater China. This model provides the company with upfront payments, potential development and commercial milestones totaling approximately $110 million, and tiered royalties on net sales. The company’s primary business segments focus on the discovery and development of next-generation immune modulators derived from T cell-driven research, with a pipeline led by rademikibart (an IL-4Rα antagonist) and icanbelimod (an S1P1 modulator). Connect Biopharma competes directly with major industry players such as Sanofi/Regeneron (Dupixent), Lexeo Therapeutics, and Prothena, positioning itself as a best-in-class alternative with a differentiated pharmacologic profile designed for faster onset and superior efficacy in treating acute exacerbations of asthma and COPD. As of February 2026, the company is led by Chief Executive Officer Barry Quart, Pharm.D., and President David Szekeres, both of whom joined in June 2024 following senior leadership roles at Heron Therapeutics and Ardea Biosciences. The founding team includes Dr. Zheng Wei and Dr. Wubin (Bill) Pan, who remain active as board members and advisors to ensure continuity of the company’s T cell biology expertise. The leadership team is further bolstered by Kleanthis G. Xanthopoulos, Ph.D., who serves as the Chair of the Board of Directors. Notable institutional backing and board representation include James Zuie-chin Huang of Panacea Venture and Jim Schoeneck, reflecting a strong investor base that supports a cash runway extending into 2027 through critical Phase 2 and Phase 3 clinical catalysts.